Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGV 001

Drug Profile

IGV 001

Alternative Names: IGF-1R antisense therapy; IGF-1R/AS ODN; IGV-001; Insulin growth factor receptor type 1 antisense therapy; Type 1 insulin growth factor receptor antisense therapy

Latest Information Update: 13 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thomas Jefferson University Hospital
  • Developer Imvax; Thomas Jefferson University Hospital
  • Class Antisense oligonucleotides; Cancer vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 10 Sep 2019 Phase I development is ongoing USA
  • 10 Sep 2019 Imvax plans a phase I trial for Glioblastoma in USA
  • 10 Sep 2019 Imvax plans a phase II trial for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top